



GEORGIA DEPARTMENT  
OF COMMUNITY HEALTH

## Georgia Department of Community Health

# DRUG UTILIZATION REVIEW BOARD MEETING

Department of Community Health  
2 Peachtree Street – **5<sup>th</sup> Floor Board Room**  
Atlanta, Georgia 30303

**May 1, 2018**

*This page intentionally left blank*



## DRUG UTILIZATION REVIEW BOARD MEETING

### AGENDA

*2 Peachtree Street - 5<sup>th</sup> Floor DCH Board Room*

*Atlanta, Georgia 30303*

**Tuesday, May 1, 2018**

**10:00 a.m. to 4:00 p.m.**

<b>CALL TO ORDER</b>	<i>Burton L. Lesnick, M.D., FAAP, Chair</i>
<b>MINUTES FROM PREVIOUS MEETING</b>	<i>Chair</i>
<b>EXTERNAL COMMENTS SESSION</b>	<i>Chair</i>
<b>OPIOIDS PRESENTATION</b>	<i>Afzal Mistry, PharmD, NorthStar</i>
<b>CLINICAL REVIEWS</b>	<i>Afzal Mistry, PharmD, NorthStar Chad Nicholson, PharmD, NorthStar Emily Baker, PharmD, BCPS, NorthStar</i>
➤ <b>New Drugs</b>	
● Hemlibra	
● Rebinyn	
● Symproic	
<b>ADJOURNMENT OF OPEN SESSION</b>	<i>Chair</i>
<b>EXECUTIVE SESSION</b>	<i>Nina Bandali, PharmD, Pharmacist Account Manager, Magellan Rx Management</i>
<b>RECONVENING OF OPEN SESSION</b>	<i>Chair</i>
<b>BOARD'S RECOMMENDATIONS AND VOTES</b>	<i>Chair</i>
<b>FUTURE AGENDA ITEMS</b>	<i>Chair</i>
<b>ADJOURNMENT OF MEETING</b>	<i>Chair</i>

*This page intentionally left blank*

**Department of Community Health  
Drug Utilization Review Board (DURB)  
MINUTES  
Tuesday, February 6, 2018**

**MEMBERS PRESENT**

Burton L. Lesnick, M.D., FAAP, Chair  
M. Celeste Fowler, Pharm.D., Vice-Chair  
Gurinder J.S. Doad, M.D.  
Rod M. Duraski, M.D., FACP, MBA  
Deborah Fincher, M.S., R.Ph  
Yolanda P. Graham, M.D.  
J. Russell May, Pharm.D.  
Osgood (Drew) A. Miller, R.Ph.  
Brent L. Rollins, R.Ph., Ph.D

**MEMBERS ABSENT**

Mia Avery, Pharm.D.  
Doug Collins, M.D.  
Glenda Wrenn Gordon, M.D.  
Robyn Lorys, Pharm.D.  
Danny A. Toth, R.Ph.

**Staff**

Peter D'Alba, R.Ph., Pharmacy Director, Pharmacy Services  
Gilletta Gray, R.Ph., Clinical Manager, Pharmacy Services  
Lori Garner, MHS, MBA, R.Ph., Pharmacist, Pharmacy Services  
Maria Lucas, Pharmacy Program Specialist, Pharmacy Services  
Rebecca Morrison, Pharmacy Program Specialist, Pharmacy Services  
Karla Forbes, Pharm.D., Program Integrity

**NorthStar HealthCare Consulting**

Emily Baker, Pharm.D., BCPS, MHA, MBA, President  
Afzal "Fez" Mistry, Pharm.D., Clinical Pharmacist  
Chad Nicholson, Pharm.D., Clinical Pharmacist

**OptumRx**

Talmahjia "Tami" Sweat, Pharm.D., Director, Clinical Management

**Change Healthcare**

Doug Martin, Pharm.D., Pharmacy Project Manager

**Care Management Organizations**

Turkesia Robertson-Jones, Pharm.D., CareSource

**Call to Order**

The Drug Utilization Review Board (DURB/DUR Board/Board) held its first meeting for the calendar year on February 6, 2018. The Chair, Burton L. Lesnick, M.D., FAAP, called the meeting to order at 10:01am.

Tuesday, February 6, 2018

**Comments from the Department**

There were no comments from the Department.

**Minutes from the Previous Meeting**

Chair Lesnick asked for corrections or changes to the minutes from the November 7, 2017 meeting. A motion was made (Rod M. Duraski, M.D., FACP, MBA), seconded (J. Russell May, Pharm.D.), and carried to approve the minutes as written.

**External Comments Session**

External comments were presented to the Board from the following:

- A letter from Ryan Ford, M.D. (Emory Transplant Center) – requested to not require use of Mavyret before Vosevi.

Disclosure form was completed by Dr. Ryan Ford and was reviewed by the Department.

**New Drug Reviews**

Clinical information for the following new drugs, in the market six months or more, was presented for discussion and recommendations. The complete detailed drug summary is in the New Drugs for Review section of the DUR Board binder.

Therapeutic Class	Drugs	Presenter
<b>Cytokine Modulators – Rheumatoid Arthritis</b>	<i>Kevzara</i>	Afzal “Fez” Mistry, Pharm.D.
<b>Cytokine Modulators – Psoriasis</b>	<i>Siliq</i> <i>Tremfya</i>	Chad Nicholson, Pharm.D.
<b>Antivirals, Hepatitis C Direct-Acting Agents</b>	<i>Vosevi</i>	Chad Nicholson, Pharm.D.
<b>Antiparkinson Agents</b>	<i>Xadago</i>	Afzal “Fez” Mistry, Pharm.D.

The Board discussed the drug information, provided comments, and raised questions on the following:

- Kevzara – all biologics products equally efficacious; UptoDate recommends using a TNF biologic after failure of a TNF biologic; ACR guidelines recommends using a non-TNF biologic after failure of a TNF biologic; haven’t seen biologics used as first line; Kevzara studied as monotherapy; not unreasonable to try methotrexate because of costs but if Kevzara is superior, then would want to start patients on that; length of time to determine treatment failure – 3-6 months; prescribing by specialist not part of PA process; drug increases on time approximately 1 hour.
- Xadago – this drug is a reversible inhibitor but not sure if related to decreased dyskinesia; no trials comparing with other MAO-B inhibitors; amantadine can be used; to address off

**Department of Community Health  
Drug Utilization Review Board (DURB)  
MINUTES**

**Tuesday, February 6, 2018**

episodes, can alter dosing (dose increase, frequency) and adjustment in diet, extended release formulation-could use short term; higher frequency-compliance becomes issue; drug increases on time approximately 1 hour.

- Soliq/Tremfya – require step through of Cosentyx and Humira x 3 months; 10% BSA requirement (palm of hand, face – caveat built in criteria)

**DCH Decisions**

DCH Decisions from the November 2017 DUR Board meeting were provided in the DCH Decision section of the DUR Board binder.

**Upcoming Meetings**

The following upcoming meetings were published in the DURB binder:

- Drug Utilization Review Board  
2 Peachtree Street NW  
5<sup>th</sup> Floor Board Room  
Atlanta, Georgia 30303

Tuesday, May 1, 2018

Tuesday, August 7, 2018

Tuesday, November 6, 2018

**Disclosure Forms**

Disclosure forms were received and reviewed by the Department for completeness for all Board members attending the meeting.

**Adjournment of Open Session**

The DUR Board voted to close the open meeting pursuant to the Open Meeting Act of Georgia Section 50-14-1 – 50-14-6 and pursuant to Federal Law Section 1396R-8B3D. The individuals recorded in attendance with the Board members were from the Department of Community Health, Change Healthcare, NorthStar HealthCare Consulting, and OptumRx. Pharmacy students, Kim Ba (UGA), Paige Eber (UGA), Michelle Leathwood (pharmacy resident, UGA), Andrew Mote (PCOM), Rick Ejifoma (PCOM), and Anuj Patel (PCOM) and CMO representative, Turkesia Robertson-Jones, Pharm.D. (CareSource), attended the closed session with Board members. A motion was made by Osgood (Drew) A. Miller, R.Ph., and seconded by Rod M. Duraski, M.D., FACP, MBA, to adjourn the open session and approve the closed session. There was a unanimous vote approving the closed session. The Chairman, Burton L. Lesnick, M.D., FAAP, adjourned the open session at approximately 11:20am, at which time members took a break then reconvened for the executive (closed) session.

**Executive Session**

The Executive Session was held from 11:30am to 11:55am.

**Reconvening of Open Session**

The DUR Board reconvened for the open session at 12:02pm.

Tuesday, February 6, 2018

### **Board's Recommendations to the Department**

After all clinical and financial evaluations and discussions, the DUR Board voted and presented the Department with the following recommendations for changes to the Preferred Drug List (PDL). All motions and votes are noted in Attachment A.

## **New Drugs Classes**

### **Cytokine Modulators, Rheumatoid Arthritis**

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Kevzara (Subcutaneous) Injection*.

### **Cytokine Modulators, Psoriasis**

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Siliq (Subcutaneous) Injection* and *Non-Preferred* status with *Prior Authorization* for *Tremfya (Subcutaneous) Injection*.

### **Antivirals, Hepatitis C Direct-Acting Agents**

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Vosevi (Oral) Tablet*.

### **Antiparkinson Agents**

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Xadago (Oral) Tablet*.

### **Future Agenda Items**

There were no future agenda items noted.

### **Acknowledgements**

Yolanda P. Graham, M.D., was recognized for being awarded Psychiatrist of the Year for the State of Georgia.

### **Conclusion**

At the conclusion of the reconvened open session and no other business for discussion, there was a unanimous decision to adjourn the meeting. Chair Lesnick adjourned the meeting at 12:05pm.

THESE MINUTES ARE HEREBY APPROVED AND ADOPTED, THIS THE \_\_\_\_\_  
DAY OF \_\_\_\_\_, 2018.

# Drug Utilization Review Board

Motions - Votes - **New Drugs**

**FEBRUARY 6, 2018**

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
<b>Cytokine Modulators, Rheumatoid Arthritis</b>	Kevzara (Subcutaneous) Injection	N/A	NPPA		
<b>Board Members - Present</b> <i>(Strike out, when absent)</i>	<b>Motion Maker (v)</b>	<b>Secinded By (v)</b>	<b>VOTES</b>		
			<b>YES (v)</b>	<b>NO (v)</b>	<b>ABSTAIN (v)</b>
1 Doad, Gurinder J.S., M.D.-			√		
2 Duraski, Rod, M.D.	√		√		
3 Fincher, Deborah W., M.S., R.Ph.			√		
4 Fowler, M. Celeste, Pharm.D. - <b>Vice</b>			√		
5 Graham, Yolanda, M.D.			√		
6 Lesnick, Burton, M.D. - <b>Chair</b>			√		
7 May, J. Russell (Rusty)			√		
8 Miller, Osgood (Drew) A. R.Ph.		√	√		
9 Rollins, Brent L., R.Ph., Ph.D.			√		
<b>TOTAL</b>			<b>9</b>	<b>0</b>	<b>0</b>
<b>Board Members - Absent</b>					
1 Avery, Mia, Pharm.D.					
2 Collins, Douglas, M.D.					
3 Gordon, Glenda Wrenn					
4 Lorys, Robyn Pharm.D.					
5 Toth, Danny, R.Ph.					

# Drug Utilization Review Board

Motions - Votes - **New Drugs**

**FEBRUARY 6, 2018**

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
<b>Cytokine Modulators, Psoriasis</b>	Siliq (Subcutaneous) Injection	N/A	NPPA		
	Tremfya (Subcutaneous) Injection	N/A	NPPA		
<b>Board Members - Present</b> <small>(Strike out, when absent)</small>	<b>Motion Maker (v)</b>	<b>Seconded By (v)</b>	<b>VOTES</b>		
			YES (v)	NO (v)	ABSTAIN (v)
1 Doad, Gurinder J.S., M.D.-			√		
2 Duraski, Rod, M.D.			√		
3 Fincher, Deborah W., M.S., R.Ph.		√	√		
4 Fowler, M. Celeste, Pharm.D. - <b>Vice</b>			√		
5 Graham, Yolanda, M.D.			√		
6 Lesnick, Burton, M.D. - <b>Chair</b>			√		
7 May, J. Russell (Rusty)	√		√		
8 Miller, Osgood (Drew) A. R.Ph.			√		
9 Rollins, Brent L., R.Ph., Ph.D.			√		
<b>TOTAL</b>			<b>9</b>	<b>0</b>	<b>0</b>
<b>Board Members - Absent</b>					
1 Avery, Mia, Pharm.D.					
2 Collins, Douglas, M.D.					
3 Gordon, Glenda Wrenn					
4 Lorys, Robyn Pharm.D.					
5 Toth, Danny, R.Ph.					

# Drug Utilization Review Board

Motions - Votes - New Drugs

FEBRUARY 6, 2018

New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
<b>Antivirals, Hepatitis C Direct-Acting Agents</b>		Vosevi (Oral) Tablet	N/A	NPPA		
<b>Board Members - Present</b> <span style="color: red; font-size: small;">(Strike out, when absent)</span>		<b>Motion Maker (v)</b>	<b>Seconded By (v)</b>	<b>YES (v)</b>	<b>VOTES</b> <b>NO (v)      ABSTAIN (v)</b>	
1	Doad, Gurinder J.S., M.D.-			√		
2	Duraski, Rod, M.D.			√		
3	Fincher, Deborah W., M.S., R.Ph.			√		
4	Fowler, M. Celeste, Pharm.D. - <b>Vice</b>		√	√		
5	Graham, Yolanda, M.D.			√		
6	Lesnick, Burton, M.D. - <b>Chair</b>			√		
7	May, J. Russell (Rusty)			√		
8	Miller, Osgood (Drew) A. R.Ph.			√		
9	Rollins, Brent L., R.Ph., Ph.D.	√		√		
<b>TOTAL</b>				<b>9</b>	<b>0</b>	<b>0</b>
<b>Board Members - Absent</b>						
1	Avery, Mia, Pharm.D.					
2	Collins, Douglas, M.D.					
3	Gordon, Glenda Wrenn					
4	Lorys, Robyn Pharm.D.					
5	Toth, Danny, R.Ph.					

# Drug Utilization Review Board

Motions - Votes - **New Drugs**

**FEBRUARY 6, 2018**

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
<b>Antiparkinson Agents</b>	Xadago (Oral) Tablets	N/A	NPPA		
<b>Board Members - Present</b> <small>(Strike out, when absent)</small>	<b>Motion Maker (v)</b>	<b>Seconded By (v)</b>	<b>YES (v)</b>	<b>VOTES</b>	
				<b>NO (v)</b>	<b>ABSTAIN (v)</b>
1 Doad, Gurinder J.S., M.D.-			✓		
2 Duraski, Rod, M.D.			✓		
3 Fincher, Deborah W., M.S., R.Ph.		✓	✓		
4 Fowler, M. Celeste, Pharm.D. - <b>Vice</b>			✓		
5 Graham, Yolanda, M.D.	✓		✓		
6 Lesnick, Burton, M.D. - <b>Chair</b>			✓		
7 May, J. Russell (Rusty)			✓		
8 Miller, Osgood (Drew) A. R.Ph.			✓		
9 Rollins, Brent L., R.Ph., Ph.D.			✓		
<b>TOTAL</b>			<b>9</b>	<b>0</b>	<b>0</b>
<b>Board Members - Absent</b>					
1 Avery, Mia, Pharm.D.					
2 Collins, Douglas, M.D.					
3 Gordon, Glenda Wrenn					
4 Lorys, Robyn Pharm.D.					
5 Toth, Danny, R.Ph.					

## Drug Utilization Review Board Meeting

**February 6, 2018**

Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
<b>Drug Reviews</b>			
<b>Cytokine Modulators, Rheumatoid Arthritis</b>			
	Kevzara (Subcutaneous) Injection	Non-PDL	NP/PA
<b>Cytokine Modulators, Psoriasis</b>			
	Siliq (Subcutaneous) Injection	Non-PDL	NP/PA
	Tremfya (Subcutaneous) Injection	Non-PDL	NP/PA
<b>Antivirals, Hepatitis C Direct-Acting Agents</b>			
	Vosevi (Oral) Tablet	Non-PDL	NP/PA
<b>Antiparkinson Agents</b>			
	Xadago (Oral) Tablet	Non-PDL	NP/PA

PDL=Preferred Drug List; P=preferred; NP=non-preferred; PA=prior authorization

*This page intentionally left blank*

**Georgia Department of Community Health (GDCH)  
Opportunities for Pharmaceutical Manufacturer Input on Clinical  
Recommendations and Clinical Management Strategies by the  
Drug Utilization Review Board**

Clinical Information and Clinical Management Strategies relevant to the GDCH Medicaid Fee-For-Service program will be presented to the Drug Utilization Review Board (DURB) at each meeting through OptumRx by its vendor NorthStar HealthCare Consulting (NHC). Manufacturer input on new and existing drugs is welcomed and appreciated using these opportunities. **Please note that new drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

**Ongoing Opportunity:**

**DUR Board Meeting Process:** Drugs, therapeutic classes and/or supplemental rebate classes under review will be posted to the DCH website at <http://dch.georgia.gov/durb-meeting-information> approximately 30 days prior to the Manufacturers' Forum. Input specific to the drugs under review from manufacturers are made directly to NHC via [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com) and reported as appropriate by NHC at subsequent DURB meetings. NHC will pass relevant manufacturer-submitted electronic materials to the DURB members via a secure FTP site.

Upon review of information, and based on its expertise and discussions, the DURB makes recommendations to GDCH.

**Opportunity to Appeal to GDCH:**

**GDCH Review Process:** DURB recommendations are reviewed by GDCH for final decisions. Manufacturers may request an appeal meeting directly with GDCH after conclusion of each quarterly DURB meeting and **this appeal meeting must be conducted within 10 business days following the DURB meeting.** **Contact: Shirmary Hodges at (404) 656-4044 or [shodges@dch.ga.gov](mailto:shodges@dch.ga.gov)**

**Presentation Opportunity:**

**Manufacturers' Forum:** A forum prior to each relevant DURB meeting whereby manufacturers may present:

- 1) Clinical information relevant to a new drug on the market or a drug that is part of a therapeutic or supplemental rebate class under review by the DURB at the next meeting.
- 2) Clinical information relevant to ongoing NHC/OptumRx clinical management strategies (e.g. review of drug benefit plan designs, new drugs coming to market, new indications, etc.) as deemed necessary by NHC/OptumRx.

Please see the Manufacturers' Forum Announcement at <http://dch.georgia.gov/durb-meeting-information>.

**Questions not addressed in this document may be sent to NorthStar  
HealthCare Consulting by e-mail: [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com)**

*This page intentionally left blank*

**2018**

## **Upcoming Meetings**

### **Drug Utilization Review Board Meeting**

2 Peachtree Street, N.W.

5<sup>th</sup> Floor Board Room

Atlanta, Georgia 30303

Tuesday, August 7, 2018: 10:00am – 2:00pm

Tuesday, November 6, 2018: 10:00am – 2:00pm

*This page intentionally left blank*

### Drug Utilization Review Board

<b>Board Member</b>	<b>Credentials</b>	<b>Specialty/Area of Expertise</b>	<b>Company Name</b>
<b>Burton L. Lesnick, Chair</b>	M.D., FAAP	Pediatrics/Pediatric Pulmonology	Children's Healthcare of Atlanta
<b>M. Celeste Fowler, Vice-Chair</b>	Pharm.D., HCMBA	340B Pharmacy	Piedmont Henry Hospital
<b>Mia Avery</b>	Pharm.D.	Oncology Pharmacy	Emory University Hospital Winship Cancer Institute
<b>Douglas C. Collins</b>	M.D.	Hematology/Oncology	Metro Hematology-Oncology, PC
<b>Gurinder J.S. Doad</b>	M.D., Ph.D.	Family Practice	Southwest Georgia Family Medicine and Mercer University School of Medicine
<b>Rod M. Duraski</b>	M.D., FACP, MBA	Internal Medicine	West Georgia Health
<b>Deborah W. Fincher</b>	R.Ph., M.S.	HIV/AIDS Pharmacy	Pride Medical Pharmacy
<b>Glenda Gordon</b>	M.D.	Psychiatry, Academia - Professor	Morehouse School of Medicine
<b>Yolanda P. Graham</b>	M.D.	Child and Adolescent Psychiatry	Devereux Georgia Treatment Network
<b>Robyn Lorys</b>	Pharm.D.	Academia - Professor	Mercer University College of Pharmacy
<b>J. Russell May</b>	Pharm.D.	Academia - Professor	University of Georgia College of Pharmacy
<b>Drew A. Miller</b>	R.Ph.	Retail Pharmacy	Wynn's Pharmacy
<b>Brent L. Rollins</b>	R.Ph., Ph.D.	Academia - Professor	Philadelphia College of Osteopathic Medicine School of Pharmacy
<b>Danny A. Toth</b>	R.Ph.	Pharmacy Benefit Plans	Timber Ridge Consultants, LLC